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We show that a molecular scaffold can be utilized to
convert a receptor binding aptamer into a receptor
agonist.Many receptors (including tumornecrosis re-
ceptor family members) are activated when they are
multimerized on the cell surface. Molecular scaffolds
have been utilized to assemble multiple receptor
binding peptide ligands to generate activators of
such receptors. We demonstrate that an RNA ap-
tamer that recognizes OX40, a member of the tumor
necrosis factor receptor superfamily, can be con-
verted into a receptor-activating aptamer by assem-
bling twocopiesonanolignucleotide-basedscaffold.
The OX40 receptor-activating aptamer is able to
inducenuclear localizationof nuclear factor-kB,cyto-
kine production, and cell proliferation, as well as en-
hance the potency of dendritic cell-based tumor
vaccines when systemically delivered to mice.
INTRODUCTION
RNA ligands or aptamers that bind protein targets can be iso-
lated from a combinatorial library of RNA sequences through
the SELEX process (Ellington and Szostak, 1990; Tuerk and
Gold, 1990; Fitzwater and Polisky, 1996). Aptamers are an
emerging class of therapeutic agents that are potentially useful
in a wide variety of therapeutic settings, including tumor immu-
notherapy (Nimjee et al., 2005; Santulli-Marotto et al., 2003).
RNA aptamers offer several advantages over traditionally used
therapeutic agents, including the ability to inhibit protein-protein
interactions (Burmeister et al., 2005), an avoidance of immuno-
genicity (Macugen, 2007), and the opportunity to rapidly reverse
the aptamer’s activity via an ‘‘antidote’’ oligonucleotide (Rusconi
et al., 2002; Dyke et al., 2006; Nimjee et al., 2006). Here we
sought to determine if a molecule scaffold could be employed
to convert a receptor binding aptamer into a receptor agonist,
targeting the cell surface receptor OX40.
The modulation of receptor signaling during immune re-
sponses has tremendous potential for the treatment of
a wide range of diseases, including inflammation, autoim-Chemistry & Biology 1mune disease, heart disease, and cancer. In particular, the
development of therapeutic agents that can modulate the
function of the tumor necrosis factor (TNF) receptor super-
family has received much attention. Because these receptors
are activated by ligand-induced multimerization on the cell
surface, the development of multimeric receptor binding
ligands has been a particular focus. For example, Fournel
et al. (2005) recently demonstrated that a molecular scaffold
could be decorated with peptide ligands that recognize the
TNF receptor family member CD40, and this multivalent
ligand could activate CD40 receptor function. Here we evalu-
ate whether such a scaffold approach can be employed to
convert an aptamer that recognizes the OX40 receptor into
a receptor agonist.
OX40 (CD134, TNFRSF4) is also member of the TNF family of
receptors. OX40 is expressed on the surface of activated T cells,
and interaction with its ligand, OX40 ligand, leads to increased
immune function manifested by T cell proliferation and cytokine
production (Weinberg, 2002; Sugamura et al., 2004; Watts,
2005). As with many other receptors involved in modulating
immune cell function (e.g., CD28, CD40, 4-1BB) (Melero et al.,
2007), agonistic antibodies targeting OX40 have been developed
(al-Shamkhani et al., 1996). In vitro and in vivo studies have dem-
onstrated that such antibodies can enhance tumor immune re-
sponses by inducing dimerization of the OX40 receptor on the
cell surface. The promise of the monoclonal antibody preclinical
data led to a phase I clinical trial with OX40 agonistic antibodies
as potential cancer therapeutics (Weinberg et al., 2006). Unfortu-
nately, the murine origin of the antibody used in this trial gener-
ated concern about the possibility of antimurine immune re-
sponses following a single administration. Thus, in the only
clinical trial that has been reported, the safety and efficacy of
OX40 antibody treatment could not be established through mul-
tiple administrations (Morris et al., 2007). More recently, a trimeric
OX40 ligand fused to the human IgG Fc has been developed as
an alternative OX40 agonist for use in patients, but its in vitro and
in vivo functionality remains to be determined (Morris et al.,
2007). As an alternative to such protein-based agents, we sought
to determine if RNA aptamers could be utilized to stimulate mu-
rine OX40 function. Here we describe how a malleable oligonu-
cleotide-based molecular scaffold can be employed to convert
an RNA aptamer against murine OX40 into a receptor-activating
aptamer.5, 675–682, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 675
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Isolation of OX40 Aptamers and Identification
of Aptamer Sequences
RNA aptamers specific to the T cell costimulatory receptor OX40
were isolated by the SELEX method (Ellington and Szostak,
1990; Tuerk and Gold, 1990; Fitzwater and Polisky, 1996). Mu-
rine OX40 human IgG Fc fusion protein was coupled to protein
G-coated beads to facility RNA partitioning. To avoid amplifica-
tion of RNA binding undesired portions of this construct, RNA
capable of interacting with the human IgG Fc or protein G alone
were removed from the randomized RNA library via preincuba-
tion with these proteins. This ‘‘precleared’’ RNA pool was then
added to the immobilized murine OX40 fusion protein. The
OX40 binding RNA was reverse transcribed and amplified by
RT-PCR, and a secondary enriched RNA library was created
by in vitro transcription. This ‘‘selection round’’ was repeated
10 times with enhancing stringency, defined as increasing
RNA:protein ratios. Selection progress was monitored by com-
paring binding affinities of the SELEX round RNA to the protein
after each round of selection (Figure 1A). After binding affinity
no longer increased following additional selection rounds, the
sequences of the isolated aptamers were determined.
As shown in Figure 1B, this process yielded a number of RNA
aptamers that bound OX40 with varying affinities (KD = 8–625
nM). Aptamer 9.8 was chosen for further study, since it had the
highest affinity for the OX40 fusion protein. To ensure that RNA
aptamer 9.8 bound OX40 and not the Fc portion of IgG or protein
G that were used in the selection, we performed additional bind-
ing studies. Such analysis demonstrates that aptamer 9.8 binds
the extracellular domain of murine OX40 (see Figure S1 in the
Supplemental Data available online).
To control for nonspecific activity, we created a mutant
aptamer containing two point mutations (aptamer 9.8PM; Fig-
ure 1B) that disrupt the aptamer-OX40 interaction. To generate
the mutant aptamer, we utilized the RNA structure prediction al-
gorithm m-fold (Zuker, 2003). The lowest resulting free-energy
structure is depicted in Figure S2. We chose to mutate two nu-
cleotides in a conserved loop of the aptamer. These nucleotide
substitutions maintain the overall predicted structure of the ap-
tamer, but abolish its ability to bind OX40 (Figure 2D). This
mutant aptamer served as a control in all of our cell and in vivo
studies.
Converting the OX40 Aptamer
into a Receptor-Activating Aptamer
Unfortunately, the monomeric aptamer 9.8 is unable to stimulate
OX40 function (Figure S3). In an attempt to convey OX40 agonis-
tic activity to aptamer 9.8, we considered characteristics of
known OX40 agonists. Agonists known to functionally activate
the OX40 receptor include antibody formulations (al-Shamkhani
et al., 1996) and multimerized versions (dimerized/trimerized
[Morris et al., 2007]) of OX40s natural ligand (OX40 Ligand)
(Figure 2A). These proteins share the common feature of pos-
sessing multiple binding sites for OX40. They have the capacity
to crosslink receptor subunits, leading to receptor activation and
signaling. Therefore, we developed a DNA scaffold that is able to
bind two copies of the aptamer 9.8 (Figure 2B). DNA was chosen
for the scaffold as we wanted to avoid double-stranded RNA676 Chemistry & Biology 15, 675–682, July 21, 2008 ª2008 Elsevie(dsRNA), to address concerns about Toll-like receptor activation
due to the fact that dsRNAs have been shown to bind and acti-
vate cell surface-expressed Toll-like receptors (Kleinman et al.,
2008). The aptamer annealing sites on the scaffold were sepa-
rated by a polyethylene spacer. This spacer was chosen to pro-
vide flexibility to the assembled complex, as a model of the
structure of OX40 complexed with the OX40 ligand indicated
that the receptors in the natural receptor-ligand complex are po-
sitioned between 39 and 76 A˚ apart from one another. Incubation
of aptamer 9.8 with the DNA scaffold at a ratio of 2:1 resulted in
three different species: a DNA scaffold with two bound ap-
tamers, a scaffold with a single bound aptamer, and unbound
aptamer. The three different species were purified via native
PAGE followed by elution (Figure 2C). When two copies of
the aptamer are assembled on the DNA scaffold, they retain their
ability to bind the murine OX40 with high affinity (Figure 2D). Fur-
thermore, the aptamer dimers were shown to be capable of bind-
ing to two OX40 molecules by gel shift analysis (Figure S4).
OX40 activation is known to serve as costimulatory signal and
enhance T cell proliferation (Ali et al., 2004), induce cytokine se-
cretion (Kawamata et al., 1998), and initiate T cell signaling
events (Aggarwal, 2003). We next sought to determine if the fully
assembled DNA scaffold-dimeric aptamer complex could elicit
these effects. We primed murine T cells with the antigen Staph-
yloccocal enterotoxin B (SEB) in vivo (Figure 3A), and mice were
sacrificed and their lymph nodes removed. Single-cell suspen-
sions of the lymph node-derived cells were labeled with carboxy
fluorescein succinimidyl ester (CFSE), as outlined in the Experi-
mental Procedures (Ali et al., 2004). The fluorescently labeled
cells were restimulated with the SEB antigen in vitro in the pres-
ence of the OX40 bivalent aptamer-DNA scaffold. As shown in
Figure 3B and Figure S5, treatment of the cells with SEB in addi-
tion to either the scaffold-assembled bivalent aptamer or an
agonisitic OX40 antibody (OX86) led to an increase in cell prolif-
eration. By contrast, the mutant aptamer containing scaffold and
an isotype control antibody had no effect. Thus, a DNA scaffold
can be utilized to assemble two copies of aptamer 9.8 in close
proximity to one another and convert the OX40 aptamer into a
receptor-activating aptamer.
Activation of the OX40 receptor also results in the induction of
interferon (IFN)-g secretion (Aggarwal, 2003; Kawamata et al.,
1998). Therefore, to confirm our cell proliferation results, we eval-
uated the levels of IFN-g secreted from receptor-activating ap-
tamer-treated lymph node cells. As shown in Figure 3C, addition
of the DNA scaffold-aptamer dimer resulted in a dramatic
increase in the production of this cytokine. By contrast, the
aptamer-scaffold complex did not induce TNF-a expression, in-
dicating that the Toll-like receptors were not being stimulated by
the aptamer treatment (Figure S6). Finally, since activation of
OX40 is known to result in the increased nuclear translocation
of nuclear factor (NF)-kB (Aggarwal, 2003; Arch and Thompson,
1998), we isolated and evaluated the nuclear fractions from cells
for NF-kB following treatment with the aptamer-DNA scaffold
complex (Mi et al., 2006). As shown in Figure 3D, treatment
with either the aptamer-DNA complex or an agonistic OX40 an-
tibody resulted in NF-kB nuclear localization. By contrast, treat-
ment with the mutant aptamer-containing complex had no effect
on NF-kB localization. Collectively, these results indicate that,
when two copies of aptamer 9.8 are dimerized by a DNAr Ltd All rights reserved
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primed T cells in culture.
OX40 Receptor-Activating Aptamer Function In Vivo
To determine if the OX40 receptor-activating aptamer can
also act as an agonist in vivo, we evaluated the compound’s
ability to induce OX40 function in a tumor immunotherapy set-
ting. More precisely, we assessed its ability to enhance anti-
tumor responses generated by dendritic cells (DCs) trans-
fected with a tumor antigen (Nair and Boczkowski, 2002).
DCs are antigen-presenting cells that can be modified to
present antigens to activate T cells. One approach to supply-
ing antigens to DCs is through messenger RNA (mRNA) trans-
fection. Vaccination with antigen-pulsed DCs has been previ-
ously shown to induce tumor immune responses. To evaluate
the OX40 receptor-activating aptamer’s activity in vivo, we
evaluated its ability to enhance a DC-based antitumor vaccine
in mice.
Female C57/BL6 mice were implanted with B16-F10.9 mela-
noma tumor cells and vaccinated with DCs pulsed with either
the melanoma antigen tyrosinase-related protein 2 (TRP-2) or
actin (control) mRNA (Figure 4A). The vaccine was systemically
administered in the presence of OX40 receptor-activating ap-
tamer, mutant OX40 aptamer, OX40 agonistic antibody, or an
isotype control antibody (Nair et al., 2007). As shown in
Figure 4B, administration of DCs containing the TRP-2 antigen
alone delayed the development of a palpable tumor compared
to control antigen-treated animals, but did not lead to a cure
with all animals developing tumors by Weeks 25–30. However,
administration of either the OX40 receptor-activating aptamer
or the OX40 agonistic antibody to animals receiving the DC-
TRP-2 vaccination resulted in tumor-free survival in 30%–40%
of the animals for over 40 days. Thus, systemic administration
of the OX40-activating aptamer significantly enhanced the
Figure 1. Isolated OX40 Aptamers and
Binding to Recombinant and Cell Surface
OX40
(A) The binding affinities for the indicated SELEX
rounds to a murine OX40-IgG Fc fusion protein
were determined by differential filter binding
(RNA pool [black squares], round 3 [dark gray
squares], round 5 [medium gray squares], round
7 [light gray squares], round 9 [lightest gray
squares], and round 11 [white squares]).
(B) Summary of aptamer sequences against mu-
rine OX40, including a point mutant version of
aptamer 9.8 (9.8 PM) and their binding affinities.
The sequence of the 50 (GGGAGGACGATGCGG)
and 30 fixed regions (CAGACGACTCGCTGAGG
ATCCGAGA) have been excluded for brevity.
potency of a DC tumor vaccine in vivo
(DC-TRP-2 + control aptamer versus
DC-TRP-2 + OX40 aptamer; p% 0.05).
DISCUSSION
Through the use of the TNF receptor fam-
ily member OX40 as an example, our re-
sults demonstrate that RNA aptamers dimerized through an-
nealing to a molecular scaffold can act as receptor agonists.
RNA aptamers represent a class of molecules with inherent ad-
vantages over the use of antibodies as therapeutic agonists. In
contrast to many protein-based therapeutic agents, aptamers
can be safely administered repeatedly without eliciting com-
pound-specific antibodies (Macugen, 2007). The OX40
agonistic antibody currently in clinical development was devel-
oped in a murine host; therefore, its administration is limited to
a single dose, because of the potential to develop human anti-
mouse antibodies as a reaction to the protein of murine origin
(Morris et al., 2007). This shortcoming is particularly limiting
for treatment of chronic diseases, such as cancer. Moreover,
the potential exists for patients to develop neutralizing anti-
bodies to humanized monoclonal antibodies following repeated
administration.
Recently, we described an example of an aptamer agonist
(McNamara et al., 2007). However, the approach taken to gener-
ate this aptamer agonist is restrictive. Two aptamers were cross-
linked through the addition of two complementary sequence
extensions to form an aptamer dimer. Each stretch of 21 RNA nu-
cleotides formed a base-paired linker that is approximately 65 A˚
in length and is fairly rigid (Figure S7A). This method of aptamer
crosslinking is limiting due to the difficulty in varying crosslinker
length and the restriction to the number (Talmage et al., 1977) of
conformations the crosslinked molecule can adopt. If the paired
section is too short, stability is compromised, while further
increases in aptamer length greatly decrease aptamer yields
through in vitro transcription or chemical synthesis. Moreover
the length of the complex is critical for the formation of an
aptamer agonist, as the goal is to crosslink multiple receptor
monomers to induce signaling.
In a paper by Santulli-Marotto et al. (2003), multimerization of
two CTLA-4 dimers through aptamers that were arrayed on
Chemistry & Biology 15, 675–682, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 677
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(A) Threading-based structural model of murine OX40L bound to murine OX40. Shown is a cartoon of a trimeric murine OX40L complex (gray ribbon with transparent
surface) liganded with murine OX40 (blue) (PDB code: 2HEY). Each OX40L protomer is liganded stoichiometrically 1:1 to OX40. The shortest (39.1 A˚) and longest
(75.8 A˚) inter-OX40 distances to equivalent residues are denoted by the red dashed line.
(B) Aptamer 9.8 or point mutant were dimerized by annealing to an oligonucleotide (green) containing two sites for aptamer hybridization separated by a poly-
ethylene spacer.
(C) Dimerization of RNA aptamers through the use of a DNA scaffold. RNA aptamers were dimerized by heat annealing to a DNA scaffold at a 1:1 ratio of binding
sites. The resulting mixture of dimer (two aptamer + scaffold) and monomer (one aptamer + scaffold) were PAGE-purified with an 8% native polyacrylamide gel.
The identity of gel-eluted dimers was verified by rerunning the dimerized RNA on a PAGE gel and visualization using ethidium bromide. The image colors have
been inverted for ease of viewing.
(D) Aptamer dimers retain binding affinity to purified OX40 protein. Gel-purified aptamer dimers were radioactively labeled, and their binding affinities to murine
OX40-IgG Fc fusion protein were determined by differential filter binding. Shown are binding curves of OX40-Fc fusion protein to aptamer monomer (squares),
aptamer dimer (triangles), point mutant monomer (inverted triangles), or point mutant dimer (diamonds) (n = 3). Error bars indicate ± 1 SEM.a complementary scaffold was used as a means to increase
avidity, as illustrated in Figure S7B. However, the mode of dimer-
ization in this case does not alter the functionality of the
aptamers, as it is not designed to affect the dimerization of indi-
vidual CTLA-4 receptors, but merely increase the apparent
binding affinity through increased valency.
This study is the first demonstration of using a scaffold to ar-
range two aptamers to crosslink receptor monomers and
thereby induce receptor function. The scaffold approach is
based on a duplex formation allowing for more flexibility, as
the scaffold contains a polyethylene glycol linker (Figure S7C)
that conveys flexibility much like the hinge region in an antibody
(Figure S7D). This approach could allow for application to many
other cell surface receptors, as the scaffold can accommodate
a variety of distances and conformations much like molecular
calipers (Figure S7C). Furthermore, the scaffold-based ap-
proach taken in this study has the advantage of being amenable
to optimization. For example, to enhance the activity of this par-
ticular agonistic aptamer, a variety of modifications to the scaf-
fold could be explored: The length of the spacer that is currently678 Chemistry & Biology 15, 675–682, July 21, 2008 ª2008 Elsevier18 carbons in length could be varied to enhance this particular
aptamers’ ability to crosslink two OX40 receptor monomers
and induce signaling. Moreover, the crystal structure of the
OX40-OX40 Ligand complex revealed that the receptor and li-
gand appear to interact as two trimers (Compaan and Hymowitz,
2006). Trimerization of other tumor necrosis family members has
previously been shown to induce OX40 signaling (Fournel et al.,
2005). Thus, trimerization of the aptamer on a tripartide scaffold
may yield an even more effective agonist.
Finally, the current work is a significant advance over our pre-
viously published work with the 4-1BB aptamer with regard to
clinical relevance. In the 4-1BB aptamer case, the in vivo activity
of the aptamer complex was demonstrated following local deliv-
ery of the aptamer into a highly immunogenic, easily treatable
mastocytoma-derived tumor cell line p815 (Talmage et al.,
1977). In this paper, the aptamer agonist was directly injected
into the tumor. By contrast, the studies described in the current
paper on the OX40 receptor-activating aptamer demonstrate
that an agonistic aptamer can be used to treat a highly meta-
static, poorly immunogenic, and aggressive type of melanomaLtd All rights reserved
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Since most cancer patient applications will likely require sys-
temic administration, we believe that the model employed in
this study is more clinically relevant.
The large-scale synthesis of the full-length compound on
a scale relevant for use as a drug would be difficult, and chemical
synthesis would be low yield due to the aptamers length (80 nt).
For clinical application, however, the length of the aptamer can
be truncated to its functional core. The truncated aptamer can
then be manufactured in large scale by chemical synthesis. Fi-
nally, we anticipate that smaller amounts of agonistic aptamers
will be required to elicit phenotypic effects compared to antago-
nistic aptamers. Decrease in the dosage of aptamer required
should lower the cost of goods.
SIGNIFICANCE
The development of safe and effective receptor agonists
have become the focus ofmuch biomedical research. In par-
Figure 3. RNAAptamer Dimers Are Capable
of Enhancing SEB-Induced Proliferation,
IFN-g Production, and Nuclear Transloca-
tion of NF-kB
(A) Schematic of the experimental setup: murine T
cells were primed in vivo by i.p. injection of SEB.
After 24 hr, ingual, auxiliary, and mesenteric lymph
nodes were harvested. Cells were restimulated
with SEB ex vivo in the absence or presence of
OX40 signaling through the agonistic OX40 ap-
tamer or agonistic antibody. Effects on cell prolif-
eration, IFN-g secretion and nuclear translocation
of NF-kB were determined.
(B) The scaffold-dimerized OX40 aptamer’s effect
on proliferation of SEB-primed lymph node cells
was assessed by flow-cytometric analysis of the
CFSE-labeled cells. An OX40 antibody agonist
served as positive control. The percentage of pro-
liferating cells is noted. The summary of three in-
dependent experiments is depicted in Figure S5).
(C) OX40 activation leads to increased IFN-g re-
lease. Concentrations of IFN-g in the culture
supernatants of the previous experiment were de-
termined by ELISA. Depicted are the mean values
of three measurements. Error bars indicate ± 1
SEM; *p < 0.05.
(D) OX40 activation results in the nuclear translo-
cation of NF-kB. To measure the effect of the
OX40 receptor-activating aptamer on NF-kB
localization, cells were cultured as above in the
absence of CFSE labeling. After 72 hr of culture,
nuclei were isolated and subjected to western
blot analysis. NF-kB and the loading control
b-tubulin were detected with specific antibodies
and visualized by chemiluminescence.
ticular, agonists that can enhance im-
mune responses for treatment of vari-
ous diseases, including cancer, are
being developed and tested in preclin-
ical and clinical studies at an ever-in-
creasing rate. The traditional com-
pounds used as receptor agonists have been derived from
protein- and peptide-based chemistries. In this paper, we
demonstrate that assembly of a nucleic acid aptamer upon
an oligonucleotide scaffold can mimic the properties of
these proteinaceous agents and yield a nucleic acid-based
receptor agonist. Previously, it has been shown that dimer-
ization or multimerization of receptor subunits through mul-
tivalent ligands can induce tumor necrosis factor receptor
function, a receptor family that includes the receptors costi-
mulatory receptors OX40 and CD40. We therefore generated
a bivalent aptamer construct by annealing monomeric ap-
tamers to an oligonucleotide scaffold. We included a flexible
hinge in the scaffold to allow for adaptation to a span of in-
termolecular distances between different OX40 receptor
monomers. Just as protein-based agonists, the generated
receptor-activating aptamer can induce receptor function
ex vivo and in vivo. Beyond merely mimicking the receptor
signaling properties of protein-based agents, the agonistic
aptamer has all the advantages of RNA. Due to these
Chemistry & Biology 15, 675–682, July 21, 2008 ª2008 Elsevier Ltd All rights reserved 679
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generalizability of the approaches we describe, we antici-
pate that agonistic aptamers will emerge as a useful and
safe class of therapeutic agents.
EXPERIMENTAL PROCEDURES
Aptamer Isolation by the SELEX Method
20 Fluoro pyrimidine RNA aptamers specific to the extracellular portion of mu-
rine OX40 were isolated by the SELEX method (Ellington and Szostak, 1990;
Tuerk and Gold, 1990). An 80 nucleotide combinatorial RNA library was
created by transcription of a partially randomized DNA oligonucleotide
(50GGGGAATTCTAATACGACTCACTATAGGGAGGACGATGCGGN40 CAGA
CGACTCGCTGAGGATCCGAGA30) as previously described (Layzer and
Sullenger, 2007). This library was subjected to two ‘‘preclearing’’ steps to
remove RNAs specific to human IgG Fc as well as protein G. To this end,
the randomized RNA library was incubated with 1 nmol of human IgG1 (Sigma)
at 37C for 30 min. IgG-bound RNA was removed by centrifugation over
a 0.4 mm nitrocellulose Centrex column (Whatman). The preclearing step
was subsequently followed by incubation with magnetic protein G-coated
beads (Dynal). After bead pelleting through exposure to a magnet, the super-
natant was applied to a nitrocellulose Centrex column. All binding reactions
were carried out in 150 mM NaCl, 2 mM CaCl2, 20 mM HEPES (pH 7.4),
0.01% BSA buffer.
To enrich for OX40 binding RNAs, murine OX40 human IgG Fc fusion protein
(R&D systems) was immobilized by coupling to protein G-coated magnetic
beads (Dynal) according to manufacturer’s instructions. The bead-coupled
OX40 fusion protein was incubated with the precleared RNA pool and washed
three times with a 20-fold excess volume wash buffer (150 mM NaCl, 2 mM
CaCl2, 20 mM HEPES [pH 7.4]) to remove noninteracting RNA. RNA bound
to OX40 was extracted by a 30 min incubation in phenol:chloroform:isoamyl
alcohol (25:24:1). The RNA was amplified by reverse transcription followed
by PCR.
A secondary, enriched RNA pool was created by transcription with a 20OH
purine, 20F pyrimidine nucleotide mixture with T7 polymerase. Transcripts
were gel purified and eluted into TE, pH 7.5 (10 mM Tris [pH 7.5], 0.1 mM
EDTA). Following overnight elution, RNA was washed three times in TE (pH 7.5)
with Centricon 30 columns (Millipore).
Eleven rounds of selection were performed with increasing stringency
throughout the selection process by increasing the RNA:protein ratio in the
selection reaction. Aptamers from rounds 9 and 11 DNA were cloned into
the EcoRI/BamHI (New England Biolabs) sites in a pUC18 plasmid. Single col-
onies were sequenced and amplified by low-cycle PCR amplification followed
by in vitro transcription.
Monomeric Aptamer Binding Affinity
Binding constants were determined with filter binding assays in buffer com-
posed of 20 mM HEPES (pH 7.4), 150 mM NaCl, and 2 mM CaCl2. To deter-
mine the affinities of monomeric aptamers, serial dilutions of murine OX40
IgG Fc fusion protein (R&D systems), human IgG1 (Sigma), or protein G
(Zymed) were incubated with monomeric 50 32P-radiolabeled aptamers at
2000 cpm/ml. The mixture was passed over a stack of membranes consisting
of a Protran nitrocellulose and GeneScreen Plus nylon membrane through
application of a vacuum. The membranes were exposed to a phosphoimager
screen, scanned, and quantitated with a Molecular Dynamics Storm 840 phos-
phoimager. Finally, differential fractions of RNA bound were calculated and
graphed with Prism (Layzer and Sullenger, 2007).
Aptamer Structure Prediction
The predicted secondary structure of generated aptamers was determined by
utilizing the algorithm m-fold (http://bioweb.pasteur.fr/seqanal/interfaces/
mfold.html) with default settings for folding parameters.
Generation of Point Mutant Aptamer
The point mutant RNA aptamer was generated by in vitro transcription of DNA
template produced by annealing two oligonucleotides. One nanomole of each
oligonucleotide (50-GGGGGAATTCTAATACGACTCACTATAGGGAGGACGA
TGCGGCAGTCTGCATCGTAGGATTAGC-30and 50-TCTCGGATCCTCAGCG
AGTCGTCTGGTGGGAAAGTATACGGTGGCTAATCCTACGATGCAGACTG-30)
was heated to 95C for 5 min and annealed by cooling to 4C. A double-
stranded DNA transcription template was created by treatment with Exo-Kle-
now fragment (New England Biolabs). The reaction was stopped by the addi-
tion of 2 mM EDTA followed by phenol:chloroform and chloroform extraction.
The template was purified by triplicate washing with a Centricon 30 column
and 10 mM Tris (pH 7.5), 0.1 mM EDTA buffer. 20F modified point mutant
RNA aptamer was generated through in vitro transcription with T7 polymerase.
Aptamer Dimerization
A DNA scaffold consisting of a 20 nucleotide repeat of the complementary se-
quence of 30 fixed region of the aptamer separated by an 18 carbon spacer
(Operon) (50-TCTCGGATCCTCAGCGAGT carbon spacer TCTCGGATCCT
CAGCGAGT-30) was used to dimerize RNA aptamers. RNA aptamers were
mixed with this scaffold at a 2:1 molar ratio of RNA to scaffold. The mixture
was heated to 95C for 5 min, followed by slow cooling to room temperature.
For binding affinity determination, aptamer dimers were purified with 8% na-
tive PAGE purification, followed by overnight elution into 2 ml of TE (pH 7.5)
buffer at 4C, followed by extensive washing, as described above.
Quantification of Dimer Aptamer Binding Affinity
Radioactive labeling of monomeric RNA normally involves a dephosphorylation
step at 65C with bacterial alkaline phosphatase (Invitrogen), followed by
Figure 4. The Agonistic OX40 Aptamer
Enhances Tumor Immunity in Mice Immu-
nized with TRP-2 RNA Transfected DCs
(A) Mice (5–10/group) were subcutaneously im-
planted with 2.5 3 104 F10.9 cells in the flank
and immunized with 105 RNA-transfected DCs at
the base of each ear pinna. DCs were generated
and electroporated with TRP-2 RNA as described
in the Experimental Procedures. Mice were in-
jected with OX40 antibody, control antibody, ago-
nistic OX40 aptamer, or control point mutant
aptamer.
(B) Results of the tumor vaccination experiment.
Reported are the days to tumor onset after implan-
tation of tyrosinase-related protein-transfected
DCs in the presence or absence of OX40 induction
(DC/TRP-2 + OX40 receptor-activating aptamer [closed squares], DC/TRP-2 + control aptamer [open squares], DC/TRP-2 + OX40 antibody [closed circles], DC/
TRP-2 + isotype control [open circles]), or control antigen-transfected DCs (DC/actin + OX40 receptor-activating aptamer [closed diamonds], DC/actin + control
aptamer [bold stars], DC/actin + OX40 antibody [open diamonds], DC/actin + isotype control [light stars]). The experiment was repeated three times with similar
results. Enhancement in DC-TRP-2 immunotherapy is not significantly different (#p > 0.05) between OX40 Ab and OX40 receptor-activating aptamer.
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Agonistic Aptamer Targeting the OX40 Receptorradioactive labeling with T4 kinase and 32P g-labeled ATP. However, gel-puri-
fied RNA dimers are heat labile and, therefore, could not be heated to 65C.
Therefore, dimers were 30 radiolabeled by incubation with T4 RNA ligase (Am-
bion) according to the manufacturer’s instructions at 4C. This method leads to
a lower incorporation efficiency, but has the advantage of avoiding exposure of
the dimer to heat. Binding affinities were determined as described for the ap-
tamer monomer.
Proliferation Assay
Activation of OX40 leads to increased T cell proliferation. We therefore tested
the effect of the dimerized aptamers on activation of OX40 and the consequent
increase in lymph node cell proliferation (Ali et al., 2004). A total of 50 mg SEB
(Sigma) resuspended in phosphate-buffered saline (PBS; GIBCO, Grand Is-
land, NY) was administered to female Balb/c mice intraperitoneally. Auxillary,
inguinal, and mesenteric lymph nodes were harvested after 24 hr. Cells were
teased into single cell suspension and labeled with CFSE (Pierce) by incubat-
ing cells at a concentration of 106 cells/ml in PBS containing 5% fetal bovine
serum (FBS; HyClone) and 2 mM CFSE at room temperature for 5 min. Cells
were washed twice with PBS with 5% FBS, followed by a final wash with
RPMI containing 10% FBS.
A total of 105 cells were seeded in wells of a round bottom 96-well plate
(Corning) and were cultured for 72 hr in complete RPMI (GIBCO) containing
10% FBS, in the presence of 0.5 ng/ml SEB in a humidified chamber at
37C/5% CO2. Experimental groups also included 33 nM OX40 agonistic an-
tibody (OX86), isotype control (ebiosciences), 66 nM of aptamer dimer or point
mutant aptamer dimer. Groups were set up in five replicates and pooled for
analysis. Cell proliferation data were collected by flow cytometry with a FACS-
calibur and evaluated with CellQuest software (Becton Dickson).
Determination of IFN-g Concentration in Tissue
Culture Supernatants
Supernatants of proliferation assay replicates were pooled after 72 hr of
culture. IFN-g secretion was measured in triplicate with the Ready Set Go
Elisa kit (ebiosciences) following the manufacturer’s instructions.
Nuclear NF-kB Detection
NF-kB is translocated to the nucleus as a result of OX40 signaling. As a mea-
sure of OX40 activation, we therefore determined presence of nuclear NF-kB in
murine lymph node cells incubated with the aptamer or point mutant dimer
compared to the agonisitic OX40 antibody. Mice were injected with SEB and
lymph nodes harvested as described in the proliferation assay. Cells were
teased into single cell suspension and 105 cells per 96-well plate were seeded
in complete RPMI containing 0.5 ng/ml SEB. Aptamer dimers or antibodies
were added at a concentration of 66 nM. After 72 hr culturing, cells were pel-
leted and nuclei were isolated with to the Sigma CelLytic NuCLEAR Extraction
kit according to manufacturer’s instructions for hypotonic nuclear isolation (Mi
et al., 2006). The absorbance of the generated protein fractions at A280 was
determined. Equivalent amounts of protein were loaded onto a 4%–15% de-
naturing PAGE gel (Biorad) and transferred to a polyvinylidene difluoride mem-
brane by electroblotting. NF-kB was detected with a specific primary antibody
(Santa Cruz Biotechnology) followed by incubation with a horseradish perox-
idase-labeled secondary antibody (goat anti-rabbit; Santa Cruz Biotechnol-
ogy). Protein was visualized with the ECL plus chemiluminescence detection
kit (GE Amersham) and captured through exposure to film. Antibodies were re-
moved from the membranes by a 15 min incubation with Restore Western Blot-
ting Stripping Buffer (Pierce). Successful stripping was verified by treatment
with chemiluminescence reagents and exposure to film. The nuclear protein
loading control b-tubulin was detected through incubation with a primary
followed by a secondary HRP-conjugated antibody.
Murine Bone Marrow Precursor-Derived DC
Marrow from tibias and femurs of C57BL/6 mice were harvested followed by
treatment of the precursors with ammonium chloride Tris buffer for 3 min at
37C to deplete the red blood cells. The precursors were plated in RPMI
with 5% FCS and GM-CSF (15 ng/ml) and IL-4 (10 ng/ml). GM-CSF and IL-4
were obtained from Peprotech (Rocky Hill, NJ). Cells were plated at 106/ml
and incubated at 37C and 5% CO2. Three days later, the floating cells (mostly
granulocytes) were removed and the adherent cells replenished with freshChemistry & Biology 1GM-CSF and IL-4 containing medium. Four days later, the nonadherent cells
were harvested, washed, and electroporated with RNA.
Electroporating Murine DC with RNA
DC were harvested on Day 7, washed, and gently resuspended in Opti-MEM
(GIBCO) at 2.53 107/ml. The used DC culture media was saved as conditioned
media for later use. Cells were electroporated in 2 mm cuvettes (200 ml of DC
[5 3 106 cells] at 300 V for 500 ms using an Electro Square Porator ECM
830 [BTX, San Diego, CA]). The amount of TRP-2 or actin RNA used was
3 mg/106 DC. Cells were immediately transferred to six well plates containing
a 1:1 combination of conditioned DC growth medium and fresh RPMI with
GMCSF and IL-4. Transfected cells were incubated at 37C, 5% CO2 for
4 hr in the presence of 100 ng/ml LPS (L265L, E. coli 026:B6; Sigma), washed
twice in PBS, and then injected into mice.
Statistical Analysis
Statistical analysis was performed with the graphing software Prism. Two-
tailed, nonparametric t tests were carried out with the default parameters. Sta-
tistical analysis of in vivo data was completed with the logrank (Mantel-Haens-
zel test). Confidence intervals equal to or less than 0.05 were considered to
constitute statistical significance.
SUPPLEMENTAL DATA
Supplemental Data include seven figures and are available online at http://
www.chembiol.com/cgi/content/full/15/7/675/DC1/.
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